13F Holdings
中文EN

OTLC Oncotelic Therapeutics, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 908259 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY14,923.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE181.6%
ROA117.3%
ROIC (approx.)-3.2%
Asset turnover—

Leverage & solvency

Liabilities / assets33.4%
Debt / equity0.00x
Current ratio0.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.01x
Accruals ratio118.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$70,000——
R&D expense$4,357—$61,143$756,910$3.66M
SG&A expense$3.18M$376,013$573,726$4.85M$5.47M
Operating income-$3.19M-$3.58M-$6.65M-$9.72M-$9.13M
Interest expense——$1.04M$2.97M$2.00M
Pretax income$360.57M-$4.78M———
Income tax$111.55M————
Net income$249.28M-$4.52M-$7.90M$5.09M-$9.39M
EBITDA————-$9.12M
EPS (basic)0.590.01-0.020.01-0.03
EPS (diluted)0.59-0.01-0.020.01-0.03
Weighted avg. shares (diluted)422.23M404.40M396.17M457.30M303.08M
Balance sheet
Cash & equivalents$88,857$86,128$170,405$241,452$568,769
Receivables$51,324$18,976$18,976$19,748$19,748
Current assets$1.20M$134,211$271,737$303,164$627,295
Goodwill$2.79M$2.79M$5.99M$12.07M$21.06M
Intangibles————$821,841
Total assets$393.09M$26.68M$30.01M$36.12M$23.61M
Current liabilities$18.14M$19.20M$16.50M$16.92M$15.45M
Short-term debt—$2.42M$1.77M$390,050$359,262
Total liabilities$131.36M$19.20M$18.40M$16.92M$15.45M
Shareholders' equity$262.76M$8.25M$12.13M$19.41M$7.96M
Shares outstanding442.60M407.29M399.18M391.85M375.29M
Cash flow statement
Operating cash flow-$1.38M-$740,277-$1.32M-$1.45M-$4.43M
Financing cash flow$1.39M$656,000$1.25M$1.13M$4.53M
Depreciation & amortization————$10,148
Stock-based compensation$2.38M$0$0$902,141$763,315

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.